Home/Get Matched/NCT07070089
Recruiting
View on ClinicalTrials.gov

Testing BosSTENT implantation for pulsatile tinnitus

Official title: BosSTENT ImpLant to trEat debilitatiNg Pulse-synchronous Tinnitus

Condition: Pulsatile TinnitusSponsor: Sonorous NV, IncTarget enrollment: 90
  • 1 group
  • Sites in Ottawa and Toronto
  • Recruiting
The Ottawa Hospital, Ottawa, CanadaUnity Health Toronto - St. Michael's Hospital, Toronto, Canada

Interventions

  • Medical device

    BosSTENT implantation

    BosSTENT implantation in the transverse venous sinus

Canadian Sites (2)

2 of 2 recruiting

  • The Ottawa Hospital

    Ottawa, Canada

    Recruiting
  • Unity Health Toronto - St. Michael's Hospital

    Toronto, Canada

    Recruiting

Eligibility Criteria

See who this study is looking for35 criteria

The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.

Inclusion

  • +Male or female ≥18 - 80 years old
  • +Willing to comply with protocolProtocolThe detailed plan a study must follow.Read more → requirements and return to the treatment center for all required clinical evaluations and follow-upFollow-upContinued check-ins after the treatment part is finished.Read more →
  • +Able to provide informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more → to participate in the study
  • +Severe or catastrophic PST (THI grade ≥ 4; THI score ≥ 58) that responds to jugular vein compression.
  • +Cerebral venous sinus stenosis with the following characteristics:
  • +Transverse cerebral venous sinus
  • +\>50% stenosis by computed tomography venogram (CTV), magnetic resonance venogram (MRV), or catheter cerebral angiography
  • +Vessel diameter amenable to sizing according to Table 1 below without the need to undersize
  • +Attempted PST amelioration with at least one non-invasive therapy (i.e., refractory to non-invasive therapy)
  • +Life expectancy \>12 months

Exclusion

  • History of severe allergy to contrast/contrast media or nickel
  • Previously implanted stent in the target vessel
  • Contraindication to anticoagulant and/or antiplatelet therapy or thrombolytic drugs
  • Target vessel size that does not fall within the indicated range per Table 1 of the IFU
  • Non-pulse-synchronous tinnitus
  • Current diagnosis of papilledema
  • Dural arteriovenous fistula or arteriovenous malformation
  • History of untreated atrial fibrillation, untreated/uncontrollable hypertension, or other stroke factors
  • History of deep vein thrombosis or pulmonary embolism
  • History of heart failure, dilated cardiomyopathy, or congenital heart conditions
  • Arterial stenosis, dissection, or aneurysm
  • PST due to causes not related to cerebral venous sinus stenosis
  • Evidence of an active systemic infection
  • Venous sinus thrombosis, jugular compression, venous aberrant or tortuous anatomy that would prevent the safe delivery and deployment of the BosSTENT to the target treatment zone.
  • Cerebral venous sinus diverticulum that, in the InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →'s opinion, requires treatment other than stenting (e.g., coiling)
  • Otologic disorders that may confound PST assessments, including, but not limited to misophonia or hyperacusis
  • Hypercoagulable state or hemorrhagic or coagulation deficiency refractory to medical therapy
  • Suffered a stroke within the past 6 months
  • Platelet count \<100x109/L (100,000/µL)
  • Participation in another investigational protocolProtocolThe detailed plan a study must follow.Read more →
  • Immuno-compromised
  • Other clinical conditions, that in the opinion of the Investigator significantly compromise the ability to perform a safe and/or effective procedure
  • Incapacitated, mentally compromised or otherwise incapable of understanding and/or providing informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
  • Pregnant or nursing women (females of childbearing potential who are less than 45 years old must have a pregnancy test and provide written proof that they are not pregnant prior to inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more →)
  • Dural cerebral venous sinus stenosis secondary to an underlying condition (e.g. brain tumor) that may be treated by alternative established therapies (e.g., surgery, embolization)
5 concepts to explore on this page · up to 1,300 pointsTap any term to learn what it means.

In plain language

Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.

Learning 
What this study is

This study is testing a treatment for a condition.

This study is not organised into the usual phase numbers — that is common for device, behavioural, and diagnostic research.

From the trial registry

Built from these fields:

  • designModule.designInfo.primaryPurpose
  • designModule.phases
Who receives what

Everyone in this study is in one group and receives BosSTENT implantation.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].label
  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
How the study is run

There is only one group in this study, so there is no assignment to different treatments.

This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.

From the trial registry

Built from these fields:

  • designModule.designInfo.allocation
  • designModule.designInfo.maskingInfo.masking
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for

The study lists an age range of 18 years to 80 years.

The study is open to people of any sex.

The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.

These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.

From the trial registry

Built from these fields:

  • eligibilityModule.minimumAge
  • eligibilityModule.maximumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How big and how long

The study aims to enrol about 90 people.

The study is currently expected to finish around July 2028.

The main measurement is taken over: 3 months.

From the trial registry

Built from these fields:

  • designModule.enrollmentInfo.count
  • statusModule.completionDateStruct.date
  • outcomesModule.primaryOutcomes[].timeFrame
What the study measures

Incidence of Major adverse eventsAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (MAE) — measured over 3 months.

Improvement of pulse-synchronous tinnitus measured by a decrease of at least 2 grades or 40 points on the Tinnitus Handicap Inventory (THI) — measured over 30 days.

From the trial registry

Built from these fields:

  • outcomesModule.primaryOutcomes[].measure
  • outcomesModule.primaryOutcomes[].timeFrame

Source: NCT07070089 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.

Not medical advice. What do these terms mean?

What is being tested — in plain terms

About BosSTENT implantationDevice

BosSTENT implantation in the transverse venous sinus

From the trial registry — its own words, unedited.

What a device is here: A physical instrument, implant, app or piece of equipment being studied.

Read the full explanation → · in clinical review

Common questions

Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.

Am I eligible for this trial?

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.

What the study lists: an age range of 18 years to 80 years.

The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.

The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.

From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.maximumAge
  • eligibilityModule.eligibilityCriteria
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

From the trial registry
  • armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?

This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.

There is only one group in this study, so there is no assignment to different treatments.

From the trial registry
  • designModule.designInfo.maskingInfo.masking
  • designModule.designInfo.allocation
Who can join?

The study lists an age range of 18 years to 80 years.

It is open to people of any sex.

It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.

From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.maximumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How long would this take?

The study's main measurement is taken over: 3 months.

The study as a whole is currently expected to finish around 2028-07.

How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.

From the trial registry
  • outcomesModule.primaryOutcomes[].timeFrame
  • statusModule.completionDateStruct.date
How many people are taking part?

The study aims to enrol about 90 people.

From the trial registry
  • designModule.enrollmentInfo.count
Where is this happening?

This study lists 2 locations, including: Ottawa, Canada, Canada; Toronto, Canada, Canada.

Sites can open and close during a study, so confirm with the team before travelling.

From the trial registry
  • trial_locations

About This Trial

This study is evaluating the safety and clinical performance of the BosSTENT, a new stent designed specifically for treating pulse-synchronous tinnitus due to venous sinus stenosis. The study will evaluate the long-term safety of the BosSTENT as well as its impact on the severity of pulse-synchronous tinnitus.

Think this trial might be right for you?

Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.

See if this trial could fit you

This page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.